Not currently recruiting at UCSF
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
Summary
- Eligibility
- for females ages 18-130 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Edwin Alvarez
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Edwin Alvarez
Professor, Ob/Gyn, Reproductive Sciences, School of Medicine
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- AstraZeneca
- ID
- NCT03737643
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 1374 study participants
- Last Updated